← 483 OBSERVATION EXPLORER

FDA 483 OBSERVATION · #925 OF 1,000 MOST-CITED

Kits not FDA approved, specifically labeled

FDA cited this observation 19 times across 17 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

BY PROGRAM AREA
Human Tissue for Transplantation19
BY FISCAL YEAR
FY20233
FY20227
FY20212
FY20202
FY20192
FY20182
FY20171

How FDA worded it — real examples

Communicable disease agent tests were not FDA-licensed, approved or cleared donor screening tests.

Texas Tech University Health Sciences Center Center for Fertility and Reproductive Surgery · Lubbock, Texas · Human Tissue for Transplantation · 2023-07-26

Communicable disease agent tests were not FDA-licensed, approved or cleared donor screening tests.

Cincinnati Childrens Hospital Medical Center · Cincinnati, Ohio · Human Tissue for Transplantation · 2023-07-12

Communicable disease agent tests were not FDA-licensed, approved or cleared donor screening tests.

Arizona Center for Reproductive Endocrinology & Infertility · Tucson, Arizona · Human Tissue for Transplantation · 2023-06-28

Communicable disease agent tests were not FDA-licensed, approved or cleared donor screening tests.

Akan Biosciences Inc · Gaithersburg, Maryland · Human Tissue for Transplantation · 2022-09-30

Communicable disease agent tests were not FDA-licensed, approved or cleared donor screening tests.

Texas Tech University Health Sciences Center Center for Fertility and Reproductive Surgery · Lubbock, Texas · Human Tissue for Transplantation · 2022-09-21

Communicable disease agent tests were not FDA-licensed, approved or cleared donor screening tests.

Cabell Huntington Hospital · Huntington, West Virginia · Human Tissue for Transplantation · 2022-08-18

Examples are a representative sample of FDA's published inspection observations. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →